chronic hepatitis b: management update. - kap...
TRANSCRIPT
![Page 1: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/1.jpg)
Chronic Hepatitis B: management update.
E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting ,Kisumu 2011.
![Page 2: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/2.jpg)
Background epidemiology
Chronic hepatitis B (CHB) is an important public health problem & a leading cause of liver related morbidity & mortality worldwide (Lee WM, Hepatitis B virus infection. N Engl. J. Med. 1997, 337: 1733‐1745)
In the USA an estimated 1.25 million individuals (0.4%) of the population are infected with hepatitis B virus. ( McQuillan GM et al Am J. Public Health 1999,89:14‐18)
In Kenya the HBsAg carrier rate is about 10%(Okoth e tal)
![Page 3: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/3.jpg)
CHB: Disease progression If unRx. individuals with hepa s B are at ↑ risk of developing:‐
Liver cirrhosis Hepatic decompensation HCC Cumulative rate of morbidity & mortality from cirrhosis & HCC is highest in those who acquire HBV infection as neonates or in early childhood.
(Lee WM. N. Engl. J Med. 1997, 337: 1733‐1745)
![Page 4: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/4.jpg)
CHB: Natural history/phases of HBV infection
Immune tolerance Immune clearance Inactive carrier Resolution Reactivation (Chu CM et al. Current hepatitis reports 2004:3:123‐131
Yim HJ. Et al. Hepatology 2006;43:s173‐s181.)
![Page 5: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/5.jpg)
CHB: What defines the Phases.
Immune tolerance: ALT: Normal or minimally ↑ HBV DNA: High levels >20,000 Iu/ml (> 105 copies/ml) HBeAg +ve. , anti. Hbe –ve. Liver Histology: Minimal activity: absent or scant fibrosis
![Page 6: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/6.jpg)
CHB: What defines the Phases. Immune tolerance phase Note : Acquisition of HBV at birth or early childhood is associated
with:‐ a long latency period of immune tolerance, which might last for 2‐3
decades before immune clearance, characterized by HBeAg seroconversion to antibody to HBeAg ( anti.‐Hbe)
Late acquisition is associated with a very short immune tolerance
phase or none at all. (Chu CM et al. Current hepatitis reports 2004:3:123‐131 ( Lai CL et al Ann Intern Med 2007;147:58‐61)
![Page 7: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/7.jpg)
CHB: What defines the Phases.
Immune clearance: ( HBeAg +ve CHB) ALT: Persistently or intermi ently ↑ Serum HBV DNA ↑ > 20,000 Iu/ml Liver histology: Active with necroinflammation score ≥4. HBsAg +ve. >6months
![Page 8: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/8.jpg)
CHB: What defines the Phases.
Inactive carrier:( HBsAg > 6months) HBsAg +ve. & IgG anti HBc +ve ALT normal HBV DNA low or undetectable ( <2000Iu/ml.) HBeAg –ve. anti.‐Hbe +ve. Liver histology: Inactive with minimal fibrosis & necroinflamation score <4.
![Page 9: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/9.jpg)
CHB: What defines the Phases. Reactivation HBeAg –ve. CHB, ant. HBe +ve. & HBsAg +ve. HBV DNA↑( > 2000 Iu/ml) ALT Fluctua ng↑ Resolution (HBsAg –ve.) ALT : Normal HBeAg –ve. Anti‐Hbe +ve. HBV DNA –ve. In serum, Low levels might be detected in
the liver, in form of covalently closed circular DNA (cccDNA) Liver histology inactive.
![Page 10: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/10.jpg)
CHB: Risk factors for disease progression
Viral factors HBeAg +ve :Hazard ratio(HR) 4.2 HBV DNA level > 2000Iu/ml: HR 2.7 >20,000Iu/ml: HR 8.9‐10.7 Host factors: Male gender: HR 3.0 Advanced age(>35): HR 3.6‐8.3 Alcohol consumption: HR 2.6 Cigarette smoking HR 1.7
![Page 11: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/11.jpg)
CHB: Risk factors for disease progression
Other factors: Co infection with HCV ,HDV,or HIV HBV genotype: Worse with genotype C Presence of HBV precore & especially core promoter mutation
ALT elevation: ( Severity & Frequency )
![Page 12: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/12.jpg)
CHB: Patient evaluation:
History: e.g. F/H of :HBV infection , liver cancer Risk factors for co‐infection Alcohol use
![Page 13: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/13.jpg)
CHB( HBsAg +ve >6months): Patient evaluation:
Laboratory: Liver biochemistry (ALT, Albumin, PTI) Anti. HBc. ( IgG, IgM) HBeAg, anti‐HBe Markers of HBV replication: (HBV DNA) Check for co‐infection: HCV(anti‐HCV), HDV( anti‐HDV) HAV(IgM. anti‐HAV) HIV HBV Genotype in selected cases. TBC & Urinalysis & U/E + creatinine. Alfa feto protein
![Page 14: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/14.jpg)
CHB: Patient evaluation:
Imaging Abdominal ultrasound CT scan MRI Fibroscan: If available: Evaluates degree of fibrosis Liver biopsy
![Page 15: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/15.jpg)
CHB: Patient evaluation: Liver biopsy: Indications:‐ Pa ents with intermi ent or persistent ↑ in ALT Pts. With elevated serum HBV DNA (HBeAg +ve. >20,0000Iu/ml: HBeAg –ve: >2000Iu/ml.) but normal ALT particularly if >35yrs of age Mass lesion
![Page 16: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/16.jpg)
CHB: Patient evaluation: Practical points.
ALT: NOTE : Cut off level of upper limit of normal in pts. With CHB is lower than for commercial level.
Males: 30 Iu/ml Females: 19 Iu/ml
![Page 17: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/17.jpg)
CHB: Patient evaluation: Practical points.
HBV DNA: Serum HBV DNA must be done in all pts. With CHB It is a direct measure of viral replication It characterizes the state of replication It predicts the risk of cirrhosis, liver decompensation & HCC. This is x4 fold ↑ if HBeAg is +ve.
(Liaw YF et al Liver Int 2006;26:23‐29, de Jorgh FE et al Gastroenterology 1992;103:1630‐1635)
( 1Iu/ml = 5‐6 copies/ml )
![Page 18: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/18.jpg)
CHB: Patient evaluation: Practical points.
HBV Genotype Influences : +ve progression of disease Risk of HCC Response to therapy Genotype B: Associated with early HBeAg seroconversion at an early age
Genotype C: Associated with severe disease progression & HCC
Genotype A&B: Associated with better response to therapy ( Pegylated INF but not Nucleos(t)ide analogue)
![Page 19: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/19.jpg)
CHB: Interpretation of serological tests:(Some aspects)
Chronic hepatitis HBsAg +ve > 6 months & IgG anti HBc +ve. The onset of CHB infection is marked by continual presence of HBsAg, High serum levels of HBV DNA & +ve HBeAg in serum.
![Page 20: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/20.jpg)
CHB: Interpretation of serological tests:(Some aspects)
Occult hepatitis HBsAg –ve, IgG anti‐HBc +ve. HBV DNA +ve at low levels <2000Iu/ml Resolved hepatitis: HBsAg –ve., anti HBs +ve. anti HBc +ve. Vaccinated recipient: HBsAg –ve. anti HBs +ve, anti HBc –ve., (Emmet B Keeffe et al.Clinical Gastroenterology & hepatology 2008;6:1315‐41)
![Page 21: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/21.jpg)
![Page 22: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/22.jpg)
CHB: Goal of Therapy
1. Eliminate or significantly suppress the replication of CHB (HBV DNA suppression to possible lowest level)
This leads to :‐ ALT normalization & histological improvement THUS Prevent the progression of liver disease to cirrhosis,
decompensation, HCC (Emmet B Keeffe et al.Clinical Gastroenterology &
hepatology 2008;6:1315‐41)
![Page 23: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/23.jpg)
CHB: Goal of Therapy 2. HBeAg loss with seroconversion to anti‐Hbe. in pts. Who are HBeAg +ve at the initiation of Rx. The complete HBeAg seroconversion indicates a high
likelihood that the benefit will persist once the patient is off therapy.
Note: continue Rx. For at least 6months after seroconversion
if on NA. (Emmet B Keeffe et al.Clinical Gastroenterology & hepatology
2008;6:1315‐41) (Lok As Hepatology 2009;50:661‐662)
![Page 24: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/24.jpg)
CHB: Goal of Therapy 3. HBsAg loss: This would be a Rx. End point in pts. Who are HBeAg
–ve at the initiation of therapy However this is rarely achieved , hence an unrealistic
goal. Thus pts who are HBeAg –ve should be treated for
life if on NA (Emmet B Keeffe et al.Clinical Gastroenterology & hepatology
2008;6:1315‐41) (Lok As Hepatology 2009;50:661‐662)
![Page 25: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/25.jpg)
CHB: Drug therapy What drugs are available: 7 drugs are currently available Interferon α‐2b 5‐10 mu/dose x3/wk. Peg Interferon α‐2a 180µg s/c/wk. Lamivudine 100mg P.O. OD Adefovir 10mg/day PO OD Entecavir 0.5mg‐1.0mg/day PO, OD Telbivudine 600mg OD PO Tenofovir 300mg OD PO (Lok AS et al Hepatol 2009; 50: 661‐662)
![Page 26: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/26.jpg)
CHB: Drug therapy
What is the current recommended 1st. Line therapy: Peg Interferon alfa‐2a Exception: Pregnancy, chemotherapy prophylaxis,decompensated cirrhosis, acute infection
Entecavir Tenofovir (EASL. J hepatol 2009;50:227‐242, Liaw F et al Hepatol int. 2008; 2: 263‐283, Lok AS et al Hepatol 2009;50: 661‐662)
![Page 27: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/27.jpg)
CHB: Drug therapy NOTE: Lamivudine : Has been removed from the list of preferred 1st. Line drugs because of high rate of resistance
(Keeffe EB,et al Clin Gastroenterol Hepatol 2006;4:936‐962;
Lai CL et al N Engl J Med 2007;357:2576‐2588; Keeffe EB et al Clin Gastroenterol Hepatol 2008;6:1315‐1341 )
![Page 28: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/28.jpg)
CHB: Who to treat 1. Pt. Who is HBsAg With:‐ ↑ HBV DNA ≥ 20,000 Iu/ml & Normal ALT Should have a liver biopsy done particularly if >30yrs. Of age If histology is: Stage ≥2 &/or grade ≥2 necroinflammation. TREAT NOTE: Pt.<30yrs. Liver biopsy is optional as is in immune tolerance
phase of infection & is unlikely to have significant disease & responds poorly to Rx.
![Page 29: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/29.jpg)
CHB: Who to treat
2. ↑ ALT > ( 1‐2 xULN) with: ↑ HBV DNA ≥ 20,000 Iu/ml ( HBeAg +ve.) ≥ 2000Iu/ml (HBeAg –ve.) TREAT even without liver biopsy
![Page 30: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/30.jpg)
CHB: Who to treat
3. HBeAg +ve or –ve with : underlying cirrhosis or HIV co‐ infection TREAT If HBV DNA ≥ 2000Iu/ml
![Page 31: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/31.jpg)
CHB: Who not to treat.
1. High HBV DNA & Normal ALT Particularly if <35yrs of age: They tend to be in immune tolerance phase, thus
have minimal disease activity on liver biopsy. Those >35yrs. Do liver biopsy & Rx. If significant
stage & / or grade NOTE: Always consider ALT levels in conjunction with
serum HBV DNA & Pts. Age.
![Page 32: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/32.jpg)
CHB: Treatment end point: Nucleoside/Nucleotide analougue 1. HBeAg +ve: Rx. Until : HBeAg seroconversion + Undetectable HBV DNA by PCR Then continue for a further 6‐12 months. Rx. For life if no sero conversion 2. HBeAg –ve: HBV DNA undetectable, ALT normal HBsAg loss end point is rare so is unrealistic Hence Rx. Is life long
![Page 33: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/33.jpg)
CHB: Treatment end point:
Peg Interferon Duration is 1yr. Effect continues after stopping Rx. NOTE: Despite prolonged HBV DNA suppression
relapse is common unless there is loss & seroconversion of HBsAg
This effect is better with PEG Interferon> NA.
![Page 34: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/34.jpg)
CHB: When to consider PEG INF
Favourable predictors of response: Lower baseline HBV DNA < 109copies/ml High ALT Genotype A&B
![Page 35: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/35.jpg)
CHB: When to consider PEG INF
Specific patient demographics ‐Young ( particularly females intending to be pregnant in the near future)
‐Absence of Comorbidities Patient preference Concomitant HCV infection
![Page 36: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/36.jpg)
CHB: When not to consider PEG INF
Patients with Cirrhosis, particularly when decompensated
Pregnancy Immunosuppressed pts. Lange CM et al Hepatology 2009;50:2001‐2006 Lok AS et al Hepatology 2010;52:743‐47
![Page 37: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/37.jpg)
Cumulative rates of resistance with oral agents in Nucleos(t)ide naive pts. Drug Resistance Rate 1st. Generation Yr1 Yr2 Yr3 Yr4 Yr5 Lamivudine 24% 38% 49% 67 70% 2nd. Generation Adefovir 0% 3% 11% 18% 29% Telbivudine 4% 17% 3rd. Generation Entecavir 0.2% 0.5% 1.2% 1.2% 1.2% Tenofovir 0% 0% 0% EASL J Hepatol. 2009; 50: 227‐242, Healthcole E et al AASLD 2009; Abstract 48
![Page 38: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/38.jpg)
Resistance:Pegylated INF
None exists
![Page 39: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/39.jpg)
CHB: Management of antiviral resistance Lamivudine Restance: Add adefovir OR tenofovir Stop LAM & switch to Tenofovir/Emtricitabine.
Adefovir Resistance Add LAM OR Entecavir Stop adefovir & switch to Tenofovir/Emtricitabine
![Page 40: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/40.jpg)
CHB: Management of antiviral resistance
Entecavir Resistance: Switch to Tenofovir *Tenofovir/Emtritabine Telbivudine Resistance: Add adefovir or Tenofovir Stop Telbuvidine & switch to *Tenofovir/Emtricitabine Lok AS Hepatology 2010;52:743‐747
![Page 41: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/41.jpg)
CHB: Management of antiviral resistance
NOTE: Ac vity of Entecavir is ↓ in LAM/Telbuvidine resistance Ac vity of Tenofovir is ↓ in Adefovir resistance Lok AS Hepatology 2010;52:743‐747
![Page 42: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/42.jpg)
CHB: Management of antiviral resistance
Tenofovir: No resistance
• HIV co infected Pts. Use Tenofovir/Emtricitabine ( Truvada) Lok AS et al Hepatol 2009;50:61‐62
![Page 43: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/43.jpg)
CHB: Management of antiviral resistance
When possible , it is most beneficial to use the most potent nucleos(t)ide analogue that posses the lowest risk of genotype resistance as initial therapy for pts. With nucleos(t)ide naive disease.
The development of resistance is associated with loss of initial response & HBV DNA rebound which is followed by biochemical breakthro, & eventual reversion of histological improvement.
![Page 44: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/44.jpg)
CHB:1o Drugs
Pegylated Interferon Entecavir Tenofovir Tenofovir/Emtricitabine (TRUVADA) in HBV/HIV co‐ infected pt.
![Page 45: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/45.jpg)
CHB: Special Population Groups.
Cirrhosis: Compensated: Viral load ≥ 2000Iu/ml Preferred therapies: Entecavir & tenofovir NAs preferred over IFN as the latter can be associated with hepatic flares
Long term Rx. Preferred Lok As et al Hepatology 2009; 50:661‐662
![Page 46: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/46.jpg)
CHB: Special Population Groups.
Decompensated Cirrhosis R x. If there is any detectable HBV DNA Tenofovir or Entecavir monotherapy (Alt. LAM or Telbuvidine + Adefovir or Tenofovir) Liver transplant INF is C/I Life long Rx. Is recommended Lok AS et al. Hepatology 2009;50:661‐662
![Page 47: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/47.jpg)
CHB: Special Population Groups.
HBV/HIV Co‐infected HBV Rx.Indicated BUT HIV (HAART) not indicated HBeAg –ve.: Adefovir 10mg OD HBeAg +ve : Consider PEG INF IF Fails Adefovir Choose drug (NA) with no effect on HIV Telbivudin not recommended because of ↑HBV resistance rate
Lok As et al Hepatology 2009;50:661‐667
![Page 48: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/48.jpg)
CHB: Special Population Groups.
HBV/HIV Co‐infection HAART Indicated BUT HBV Rx. Not indicated: Choose anti HIV drugs with no effect on HBV
![Page 49: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/49.jpg)
CHB: Special Population Groups.
HBV/HIV Co‐infection HAART & HBV ( HBV DNA ≥ 2000Iu/ml) treatment Indicated. Choose drug with dual activity Preferred: Tenofovir + LAM or Emtricitabine Entecavir not recommended as is associated with induction of HIV resistant mutation
![Page 50: Chronic Hepatitis B: management update. - KAP Kenyakapkenya.org/repository/CPDs/Conferences/Annual.2011/Chronic He… · Chronic Hepatitis B: management update. E.O.Ogutu Department](https://reader036.vdocument.in/reader036/viewer/2022071210/6022125829beef520862b29b/html5/thumbnails/50.jpg)
END THANK YOU